Compare ARDX & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | CERT |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2014 | 2020 |
| Metric | ARDX | CERT |
|---|---|---|
| Price | $4.05 | $8.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $15.14 | $11.67 |
| AVG Volume (30 Days) | 2.6M | ★ 3.9M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | $2,607,000.00 | ★ $418,838,000.00 |
| Revenue This Year | $37.75 | $4.18 |
| Revenue Next Year | $34.24 | $5.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $4.71 | $4.45 |
| 52 Week High | $8.40 | $13.88 |
| Indicator | ARDX | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 34.44 | 66.11 |
| Support Level | N/A | $6.57 |
| Resistance Level | $6.47 | $9.63 |
| Average True Range (ATR) | 0.16 | 0.42 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 12.09 | 87.62 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.